Volume 4, supplement issue 1, July 2004
Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2nd Annual Meeting
59 articles in this issue
-
-
-
-
HLA DR-directed bispecific single-chain Fv antibodies for lymphoma therapy
Authors (first, second and last of 9)
-
Increased frequency of CTLA4+ TGFβ+ CD4+ CD25+ T cells in peripheral blood of patients with chronic lymphatic leukemia and multiple myeloma
Authors (first, second and last of 6)
-
-
Genetically modified natural killer cells specifically recognizing the tumor-associated antigens ErbB2/HER2 and EpCAM
Authors (first, second and last of 6)
-
Rapid functional exhaustion and deletion of cytotoxic T lymphocytes following immunization with recombinant adenovirus
Authors (first, second and last of 4)
-
High frequency of functionally active Melan-A specific T cells in a patient with progressive immunoproteasome-deficient melanoma
Authors (first, second and last of 14)
-
Adoptive T cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma: a phase I clinical study
Authors (first, second and last of 6)
-
Large scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells
Authors (first, second and last of 5)
-
Reversible HLA multimers (streptamers) for isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens
Authors (first, second and last of 9)
-
Therapeutic efficacy of RAGE-1 and MAGE-9 peptide specific cytotoxic T cell clones in renal cell carcinoma
Authors (first, second and last of 4)
-
The role of glycosylation as a modulator for signalling strength in T cells
Authors (first, second and last of 6)
-
Migration of dendritic cells to regional lymph nodes in a vaccination trial
Authors (first, second and last of 10)
-
-
-
-
-
Limiting the risk of immunogenicity by identification and removal of T-cell epitopes (DeImmunisation™)
Authors (first, second and last of 6)
-
-
Increased effector functions of a monoclonal antibody by glycoform engineering
Authors (first, second and last of 11)
-
Inhibition of signaling via erbB-receptors by antibodies that target the Lewis Y-antigen
Authors (first, second and last of 8)
-
-
Bisphosphonic acid acts as Gamma/Delta T cell activating antigen and has direct cytotoxic activity against pancreatic carcinoma cells
Authors (first, second and last of 4)
-
Regulation of p53 tumor specific immune responses in colorectal cancer patients
Authors (first, second and last of 10)
-
Assessment of genes associated with immune activation and regulation in pancreatic cancer patients
Authors (first, second and last of 10)
-
-
NFκB activation and TGFβ loss signatures are prominent ex vivo responses of peripheral blood mononuclear cells
Authors (first, second and last of 9)
-
Enrichment of functional CD8 memory T cells specific for MUC1 in Bone Marrow of Multiple Myeloma Patients
Authors (first, second and last of 10)
-
-
The kinetics of accumulation of adoptively transferred ovalbumin-specific T cells in a transgenic, ovalbumin-expressing murine tumor
Authors (first, second and last of 4)
-
Tumor-specific murine T cell receptors displace endogenous TCRs in human T cells
Authors (first, second and last of 9)
-
-
Identification of a melanoma-associated chondroitin sulfate proteoglycan (MCSP) peptide recognized by CD4+ T lymphocytes on human melanoma cells
Authors (first, second and last of 5)
-
Chimeric carrier proteins for targeted delivery of tumor antigens to professional antigen presenting cells
Authors (first, second and last of 5)
-
Particulate antigenic structures: highly immunogenic carriers for T cell epitopes derived from tumour antigens
Authors (first, second and last of 6)
-
Development, monitoring and first immunological results of a phase I/II vaccination trial using genetically modified allogeneic breast cancer cells
Authors (first, second and last of 10)
-
Dendritic cell-based immunotherapy of hormone refractory prostate carcinoma (HRPCa) – a pilot trial
Authors (first, second and last of 8)
-
The European Searchable Tumour Cell and Databank, ESTDAB, as a tool for research in cancer immunology
Authors (first, second and last of 7)
-
Efficient in vitro expression of human reverse transcriptase (hTERT) in dendritic cells of lung cancer patients using RNA electrotransfection
Authors (first, second and last of 8)
-
Parvovirus H1-induced tumor cell death enhances human immune response via crosspresentation of dendritic cells
Authors (first, second and last of 7)
-
Optimizing the antigen loading of dendritic cells with exogenous peptides
Authors (first, second and last of 4)
-
Phase I/II study of vaccination with immature and mature dendritic cells in patients with melanoma and renal cell carcinoma
Authors (first, second and last of 8)
-
Survival and homing of ex vivo expanded donor derived dendritic cells after allogeneic BMT
Authors (first, second and last of 9)
-
-
-
Peptide vaccination induces specific effector and memory T cells but fails to enhance preexisting T cell immunity
Authors (first, second and last of 6)
-
Biological characterization of CD40-activated B cells as a prerequisite for their use as cellular adjuvant in cancer vaccines
Authors (first, second and last of 5)
-
Identification of a novel epitope derived from the cancer-germline antigen, HAGE, displaying both in-vitro and in-vivo immunogenicity
Authors (first, second and last of 5)